13 Jul 2021 Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma
13 Jul 2021 Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae
13 Jul 2021 ReiThera Announces Preliminary Phase 2 Data from its COVID-19 Vaccine Candidate
09 Jul 2021 Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate
08 Jul 2021 Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor
07 Jul 2021 Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
07 Jul 2021 Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
04 Jul 2021 Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
02 Jul 2021 Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
02 Jul 2021 HDT Bio Receives Notice to Proceed from FDA for U.S. Phase 1 Clinical Trial of RNA COVID-19 Vaccine
01 Jul 2021 Zydus applies to the DCGI for EUA to launch ZyCoV-D, the world’s first Plasmid DNA vaccine for COVID-19
01 Jul 2021 Intranasal COVID-19 vaccine demonstrates single-dose efficacy in preclinical studies, in parallel with achievement of Phase 1 clinical milestone
01 Jul 2021 Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine
01 Jul 2021 SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer
30 Jun 2021 Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
30 Jun 2021 Elicio Therapeutics Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002 (AMPLIFY-201) in KRAS-Driven Cancers
29 Jun 2021 VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19
29 Jun 2021 Vaxzevria induced immunity for at least one year following a single dose and strong immune responses following either a late second dose or a third dose
29 Jun 2021 First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated
24 Jun 2021 Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
22 Jun 2021 Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
20 Jun 2021 BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma
17 Jun 2021 CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
15 Jun 2021 COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant
14 Jun 2021 Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up